Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2017

01-10-2017 | Original Article

Increased serum levels of fetuin B in patients with coronary artery disease

Authors: Kefu Zhu, Yuming Wang, Pengqin Shu, Qinyi Zhou, Jinzhou Zhu, Wenjing Zhou, Changqing Du, Chenkai Xu, Xiaowei Liu, Lijiang Tang

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

Background

Recent evidence indicates a pivotal role for fetuin B, one of the cystatin superfamily of cysteine protease inhibitors, in the pathogenesis of metabolic diseases. This study investigated whether serum fetuin B levels are associated with the presence of coronary artery disease.

Methods

Serum fetuin B levels were assessed in 87 patients with coronary artery disease (41 with acute coronary syndromes and 46 with stable angina pectoris) and 87 healthy controls using an enzyme-linked immunosorbent assay. The association of serum fetuin B levels with cardiac risk factors was analyzed.

Results

Serum fetuin B levels were significantly higher in patients with coronary artery disease than those in healthy controls (90.7 ± 32.1 vs. 110.0 ± 32.7 μg/ml, P < 0.001), extremely elevated in group with acute coronary syndromes (115.0 ± 35.2 μg/ml). Pearson correlation analysis showed that serum fetuin B levels were positively associated with the levels of total cholesterol (r = 0.276, P < 0.001), low-density lipoprotein cholesterol (r = 0.363, P < 0.001), and fasting blood glucose (r = 0.159, P < 0.05). In addition, multiple logistic regression analyses revealed that fetuin B was independently associated with the presence of coronary artery disease (OR, 1.019; 95% CI, 1.009 to 1.029; P < 0.001) and acute coronary syndromes (OR, 1.017; 95% CI, 1.006 to 1.028; P < 0.01).

Conclusions

Our data revealed that high fetuin B levels are associated with the presence of coronary artery disease and acute coronary syndromes, and that fetuin B may serve as a potential biomarker for coronary artery disease.
Literature
1.
D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, S. de Ferranti, J.P. Despres, H.J. Fullerton, V.J. Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, S. Liu, R.H. Mackey, D.B. Matchar, D.K. McGuire, E.R. Mohler 3rd, C.S. Moy, P. Muntner, M.E. Mussolino, K. Nasir, R.W. Neumar, G. Nichol, L. Palaniappan, D.K. Pandey, M.J. Reeves, C.J. Rodriguez, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani, J.Z. Willey, D. Woo, R.W. Yeh, M.B. Turner, American Heart Association Statistics, C., Stroke Statistics, S.: Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 131(4), e29–322 (2015). doi:10.​1161/​CIR.​0000000000000152​ CrossRefPubMed
2.
C.J. Murray, T. Vos, R. Lozano, M. Naghavi, A.D. Flaxman, C. Michaud, M. Ezzati, K. Shibuya, J.A. Salomon, S. Abdalla, V. Aboyans, J. Abraham, I. Ackerman, R. Aggarwal, S.Y. Ahn, M.K. Ali, M. Alvarado, H.R. Anderson, L.M. Anderson, K.G. Andrews, C. Atkinson, L.M. Baddour, A.N. Bahalim, S. Barker-Collo, L.H. Barrero, D.H. Bartels, M.G. Basanez, A. Baxter, M.L. Bell, E.J. Benjamin, D. Bennett, E. Bernabe, K. Bhalla, B. Bhandari, B. Bikbov, A. Bin Abdulhak, G. Birbeck, J.A. Black, H. Blencowe, J.D. Blore, F. Blyth, I. Bolliger, A. Bonaventure, S. Boufous, R. Bourne, M. Boussinesq, T. Braithwaite, C. Brayne, L. Bridgett, S. Brooker, P. Brooks, T.S. Brugha, C. Bryan-Hancock, C. Bucello, R. Buchbinder, G. Buckle, C.M. Budke, M. Burch, P. Burney, R. Burstein, B. Calabria, B. Campbell, C.E. Canter, H. Carabin, J. Carapetis, L. Carmona, C. Cella, F. Charlson, H. Chen, A.T. Cheng, D. Chou, S.S. Chugh, L.E. Coffeng, S.D. Colan, S. Colquhoun, K.E. Colson, J. Condon, M.D. Connor, L.T. Cooper, M. Corriere, M. Cortinovis, K.C. de Vaccaro, W. Couser, B.C. Cowie, M.H. Criqui, M. Cross, K.C. Dabhadkar, M. Dahiya, N. Dahodwala, J. Damsere-Derry, G. Danaei, A. Davis, D. De Leo, L. Degenhardt, R. Dellavalle, A. Delossantos, J. Denenberg, S. Derrett, D.C. Des Jarlais, S.D. Dharmaratne, M. Dherani, C. Diaz-Torne, H. Dolk, E.R. Dorsey, T. Driscoll, H. Duber, B. Ebel, K. Edmond, A. Elbaz, S.E. Ali, H. Erskine, P.J. Erwin, P. Espindola, S.E. Ewoigbokhan, F. Farzadfar, V. Feigin, D.T. Felson, A. Ferrari, C.P. Ferri, E.M. Fevre, M.M. Finucane, S. Flaxman, L. Flood, K. Foreman, M.H. Forouzanfar, F.G. Fowkes, M. Fransen, M.K. Freeman, B.J. Gabbe, S.E. Gabriel, E. Gakidou, H.A. Ganatra, B. Garcia, F. Gaspari, R.F. Gillum, G. Gmel, D. Gonzalez-Medina, R. Gosselin, R. Grainger, B. Grant, J. Groeger, F. Guillemin, D. Gunnell, R. Gupta, J. Haagsma, H. Hagan, Y.A. Halasa, W. Hall, D. Haring, J.M. Haro, J.E. Harrison, R. Havmoeller, R.J. Hay, H. Higashi, C. Hill, B. Hoen, H. Hoffman, P.J. Hotez, D. Hoy, J.J. Huang, S.E. Ibeanusi, K.H. Jacobsen, S.L. James, D. Jarvis, R. Jasrasaria, S. Jayaraman, N. Johns, J.B. Jonas, G. Karthikeyan, N. Kassebaum, N. Kawakami, A. Keren, J.P. Khoo, C.H. King, L.M. Knowlton, O. Kobusingye, A. Koranteng, R. Krishnamurthi, F. Laden, R. Lalloo, L.L. Laslett, T. Lathlean, J.L. Leasher, Y.Y. Lee, J. Leigh, D. Levinson, S.S. Lim, E. Limb, J.K. Lin, M. Lipnick, S.E. Lipshultz, W. Liu, M. Loane, S.L. Ohno, R. Lyons, J. Mabweijano, M.F. MacIntyre, R. Malekzadeh, L. Mallinger, S. Manivannan, W. Marcenes, L. March, D.J. Margolis, G.B. Marks, R. Marks, A. Matsumori, R. Matzopoulos, B.M. Mayosi, J.H. McAnulty, M.M. McDermott, N. McGill, J. McGrath, M.E. Medina-Mora, M. Meltzer, G.A. Mensah, T.R. Merriman, A.C. Meyer, V. Miglioli, M. Miller, T.R. Miller, P.B. Mitchell, C. Mock, A.O. Mocumbi, T.E. Moffitt, A.A. Mokdad, L. Monasta, M. Montico, M. Moradi-Lakeh, A. Moran, L. Morawska, R. Mori, M.E. Murdoch, M.K. Mwaniki, K. Naidoo, M.N. Nair, L. Naldi, K.M. Narayan, P.K. Nelson, R.G. Nelson, M.C. Nevitt, C.R. Newton, S. Nolte, P. Norman, R. Norman, M. O’Donnell, S. O’Hanlon, C. Olives, S.B. Omer, K. Ortblad, R. Osborne, D. Ozgediz, A. Page, B. Pahari, J.D. Pandian, A.P. Rivero, S.B. Patten, N. Pearce, R.P. Padilla, F. Perez-Ruiz, N. Perico, K. Pesudovs, D. Phillips, M.R. Phillips, K. Pierce, S. Pion, G.V. Polanczyk, S. Polinder, C.A. Pope 3rd, S. Popova, E. Porrini, F. Pourmalek, M. Prince, R.L. Pullan, K.D. Ramaiah, D. Ranganathan, H. Razavi, M. Regan, J.T. Rehm, D.B. Rein, G. Remuzzi, K. Richardson, F.P. Rivara, T. Roberts, C. Robinson, F.R. De Leon, L. Ronfani, R. Room, L.C. Rosenfeld, L. Rushton, R.L. Sacco, S. Saha, U. Sampson, L. Sanchez-Riera, E. Sanman, D.C. Schwebel, J.G. Scott, M. Segui-Gomez, S. Shahraz, D.S. Shepard, H. Shin, R. Shivakoti, D. Singh, G.M. Singh, J.A. Singh, J. Singleton, D.A. Sleet, K. Sliwa, E. Smith, J.L. Smith, N.J. Stapelberg, A. Steer, T. Steiner, W.A. Stolk, L.J. Stovner, C. Sudfeld, S. Syed, G. Tamburlini, M. Tavakkoli, H.R. Taylor, J.A. Taylor, W.J. Taylor, B. Thomas, W.M. Thomson, G.D. Thurston, I.M. Tleyjeh, M. Tonelli, J.A. Towbin, T. Truelsen, M.K. Tsilimbaris, C. Ubeda, E.A. Undurraga, M.J. van der Werf, J. van Os, M.S. Vavilala, N. Venketasubramanian, M. Wang, W. Wang, K. Watt, D.J. Weatherall, M.A. Weinstock, R. Weintraub, M.G. Weisskopf, M.M. Weissman, R.A. White, H. Whiteford, N. Wiebe, S.T. Wiersma, J.D. Wilkinson, H.C. Williams, S.R. Williams, E. Witt, F. Wolfe, A.D. Woolf, S. Wulf, P.H. Yeh, A.K. Zaidi, Z.J. Zheng, D. Zonies, A.D. Lopez, M.A. AlMazroa, Z.A. Memish, Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380(9859), 2197–2223 (2012). doi:10.​1016/​S0140-6736(12)61689-4 CrossRefPubMed
3.
4.
5.
K. Schmid, W. Burgi, Preparation and properties of the human plasma Ba-alpha2-glycoproteins. Biochim. Biophys. Acta. 47, 440–453 (1961)CrossRefPubMed
6.
K. Mori, M. Emoto, M. Inaba, Fetuin-A and the cardiovascular system. Adv. Clin. Chem. 56, 175–195 (2012)CrossRefPubMed
7.
C.E. Fiore, G. Celotta, G.G. Politi, L. Di Pino, Z. Castelli, R.A. Mangiafico, S.S. Signorelli, P. Pennisi, Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis. 195(1), 110–115 (2007). doi:10.​1016/​j.​atherosclerosis.​2006.​08.​052 CrossRefPubMed
8.
J.A. Bosch, G.G. Berntson, J.T. Cacioppo, F.S. Dhabhar, P.T. Marucha, Acute stress evokes selective mobilization of T cells that differ in chemokine receptor expression: a potential pathway linking immunologic reactivity to cardiovascular disease. Brain. Behav. Immun. 17(4), 251–259 (2003)CrossRefPubMed
9.
10.
R.C. Meex, A.J. Hoy, A. Morris, R.D. Brown, J.C. Lo, M. Burke, R.J. Goode, B.A. Kingwell, M.J. Kraakman, M.A. Febbraio, J.W. Greve, S.S. Rensen, M.P. Molloy, G.I. Lancaster, C.R. Bruce, M.J. Watt, B. Fetuin, Is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell. Metab. 22(6), 1078–1089 (2015). doi:10.​1016/​j.​cmet.​2015.​09.​023 CrossRefPubMed
11.
12.
13.
S.H. Jung, K.J. Won, K.P. Lee, H.J. Kim, E.H. Seo, H.M. Lee, E.S. Park, S.H. Lee, B. Kim, The serum protein fetuin-B is involved in the development of acute myocardial infarction. Clin. Sci. 129(1), 27–38 (2015). doi:10.​1042/​CS20140462 CrossRefPubMed
14.
J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, D.E. Casey Jr., W.E. Chavey 2nd, F.M. Fesmire, J.S. Hochman, T.N. Levin, A.M. Lincoff, E.D. Peterson, P. Theroux, N.K. Wenger, R.S. Wright, H. Jneid, S.M. Ettinger, T.G. Ganiats, A.M. Lincoff, G.J. Philippides, J.P. Zidar, American college of cardiology foundation/american heart association task force on practice, G.: 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 127(23), e663–828 (2013). doi:10.​1161/​CIR.​0b013e31828478ac​ CrossRefPubMed
15.
J.J. Chamberlain, A.S. Rhinehart, C.F. Shaefer Jr., A. Neuman, Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann. Intern. Med. 164(8), 542–552 (2016). doi:10.​7326/​M15-3016 CrossRefPubMed
16.
C. Lee, E. Bongcam-Rudloff, C. Sollner, W. Jahnen-Dechent, L. Claesson-Welsh, Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein. Front. Biosci. 14, 2911–2922 (2009)CrossRef
17.
E. Olivier, E. Soury, P. Ruminy, A. Husson, F. Parmentier, M. Daveau, J.P. Salier, Fetuin-B, a second member of the fetuin family in mammals. Biochem. J. 350(Pt 2), 589–597 (2000)CrossRefPubMedPubMedCentral
18.
D. Pal, S. Dasgupta, R. Kundu, S. Maitra, G. Das, S. Mukhopadhyay, S. Ray, S.S. Majumdar, S. Bhattacharya, Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18(8), 1279–1285 (2012). doi:10.​1038/​nm.​2851 CrossRefPubMed
19.
20.
S.W. Kim, H.J. Hwang, Y.M. Baek, S.H. Lee, H.S. Hwang, J.W. Yun, Proteomic and transcriptomic analysis for streptozotocin-induced diabetic rat pancreas in response to fungal polysaccharide treatments. Proteomics. 8(11), 2344–2361 (2008). doi:10.​1002/​pmic.​200700779 CrossRefPubMed
21.
22.
23.
24.
G.F. Watts, D.A. Playford, Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis. 141(1), 17–30 (1998)CrossRefPubMed
25.
C.B. Renard, F. Kramer, F. Johansson, N. Lamharzi, L.R. Tannock, M.G. von Herrath, A. Chait, K.E. Bornfeldt, Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 114(5), 659–668 (2004). doi:10.​1172/​JCI17867 CrossRefPubMedPubMedCentral
26.
J. Floehr, E. Dietzel, J. Neulen, B. Rosing, U. Weissenborn, W. Jahnen-Dechent, Association of high fetuin-B concentrations in serum with fertilization rate in IVF: a cross-sectional pilot study. Hum. Reprod. 31(3), 630–637 (2016). doi:10.​1093/​humrep/​dev340 CrossRefPubMed
27.
Metadata
Title
Increased serum levels of fetuin B in patients with coronary artery disease
Authors
Kefu Zhu
Yuming Wang
Pengqin Shu
Qinyi Zhou
Jinzhou Zhu
Wenjing Zhou
Changqing Du
Chenkai Xu
Xiaowei Liu
Lijiang Tang
Publication date
01-10-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1387-1

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue

Research Letter

Increased miR-338-3p expression correlates with invasiveness of GH-producing pituitary adenomas

Erratum

Erratum to: Ranolazine promotes muscle differentiation and reduces oxidative stress in C2C12 skeletal muscle cells

Original Article

Acid–base safety during the course of a very low-calorie-ketogenic diet

Original Article

JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia

Original Article

Development of metabolic syndrome in high-sucrose diet fed rats is not associated with decrease in adiponectin levels

Letter to the Editor

Is the hypothalamic–pituitary–adrenal axis disrupted in type 2 diabetes mellitus and is this relevant for bone health?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits